CORRECTION article

Front. Immunol., 22 April 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1601201

Corrigendum: Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment

  • VA

    Victoria A. Jennings 1* †

  • RR

    Reah Rumbold-Hall 1

  • GM

    Gemma Migneco 1

  • TB

    Tyler Barr 1

  • KR

    Katrina Reilly 1

  • NI

    Nicola Ingram 1

  • IS

    Isabelle St Hilare 2

  • SH

    Samuel Heaton 1

  • NA

    Noura Alzamel 1

  • DJ

    David Jackson 3

  • CR

    Christy Ralph 3

  • SB

    Susan Banerjee 4

  • IM

    Iain McNeish 5

  • JC

    John C. Bell 2

  • AA

    Alan A. Melcher 6

  • CI

    Carolina Ilkow 2

  • GP

    Graham P. Cook 1

  • FE

    Fiona Errington-Mais 1

  • 1. Leeds Institute of Medical Research, School of Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom

  • 2. Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • 3. Leeds Cancer Centre, St James’s Hospital, Leeds, United Kingdom

  • 4. The Royal Marsden Hospital, Fulham Road, London, United Kingdom

  • 5. Department of Cancer and Surgery, Imperial College London, London, United Kingdom

  • 6. The Institute of Cancer Research, Divisions of Radiotherapy and Imaging and Breast Cancer Research, Chester Beatty Laboratories, London, United Kingdom

Article metrics

View details

1,3k

Views

344

Downloads

In the published article, there was an error in the article title. Instead of “Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment”, it should be “Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment”.

In the published article, there was an error in the Funding statement. Several funders were omitted from the original statement. The correct Funding statement appears below.

“The authors declare that financial support was received for the research, authorship, and/or publication of this article. Ovarian Cancer Action funded Victoria Jennings, Reah Rumbold-Hall and the costs required to undertake this study. Alan Melcher was supported by CRUK (Programme grant CRM183X), Tyler Barr was supported by the Myrovlytis Trust and by an MRC/NIHR Cancer Research Transatlantic Development and Skills Enhancement Award (NIHR304246), Samuel Heaton by an MRC Discovery Medicine North (DiMeN) studentship (MR/N013840/1) and Noura Alzamel by a scholarship from Kuwait University. Nicola Ingram is supported in part by the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (BRC) (NIHR213331). Other authors were supported by their respective institutions. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care, or any other funders of this work.”

In the published article, there was an error in the Acknowledgements. Funders others than Ovarian Cancer Action were omitted from the original statement. The correct statement appears below.

“The authors would like to extend their sincere gratitude to Ovarian Cancer Action for their generous funding and support, which made this research possible. Their commitment to advancing ovarian cancer research, has been instrumental in enabling us to carry out this study. We thank the other organisations who supported the study and thank our colleagues Robert Salmond and Sandra Bell for the kind gift of materials and for their scientific input into this study.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

oncolytic virus, miRNA, tumour associated macrophage, tumour microenvironment, anti-tumour immunity

Citation

Jennings VA, Rumbold-Hall R, Migneco G, Barr T, Reilly K, Ingram N, Hilare IS, Heaton S, Alzamel N, Jackson D, Ralph C, Banerjee S, McNeish I, Bell JC, Melcher AA, Ilkow C, Cook GP and Errington-Mais F (2025) Corrigendum: Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment. Front. Immunol. 16:1601201. doi: 10.3389/fimmu.2025.1601201

Received

27 March 2025

Accepted

03 April 2025

Published

22 April 2025

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

16 - 2025

Updates

Copyright

*Correspondence: Victoria A. Jennings,

†Present address: Victoria A. Jennings, Jack Birch Unit for Molecular Carcinogenesis, Department of Biology & York Biomedical Research Institute, University of York, York, United Kingdom

‡These authors share last authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics